The Mildred S. Christian Career Achievement Award
ATS established the Mildred S. Christian Career Achievement Award to honor the memory of Dr. Christian, known to many as “Millie.” She gave much of her time and financial resources to the Academy and helped to make the ATS into an efficient and scientifically recognized organization. Many of the policies and practices used today benefit from her efforts.
The award is conferred upon an ATS Fellow who has clearly demonstrated a lasting impact on toxicological sciences. The criteria for the award include, but are not limited to, the following:
- The awardee must be an ATS Fellow in good standing as either a full ATS Fellow or ATS Emeritus. A Fellow that is a current member of the Board of Directors of ATS is not eligible to receive the award.
- The awardee must have demonstrated extraordinary scientific achievement through publications, professional activities, and/or leadership that have enhanced the practice of toxicology as judged by the Board of Directors.
The ATS Board of Directors is requesting nominations from the ATS Fellows for the 2018 Mildred S. Christian Award. If you believe an ATS Fellow meets the criteria for this award, we request that you submit a letter of support along with the nominee’s curriculum vitae to Susie Masten, Executive Director at firstname.lastname@example.org for the Board’s consideration. The deadline for receipt of nominations for the 2018 award is December 1, 2017. Nominations submitted for the 2017 award will remain in active consideration for the 2018 award.
2017 Award Recipient
Jack H. Dean, PhD, Hon ScD, ABT, ATS
Dr. Jack Dean retired in January, 2006 as President, US Science and Medical Affairs (R&D), Sanofi-Aventis, Malvern, Pennsylvania and as the Global Director of Preclinical Development for Sanofi-Aventis, SA (Paris). During his tenure at Sanofi and legacy companies (18 years) he was involved with the registration of eight NDAs for the US and global market including Plavix, Avapro, Avalide, Ambien CR, and Eloxatin as examples. He also led the reorganization of global preclinical development through three corporate mergers (Sterling-Winthrop, Synthelabo, and Aventis).
He joined Sterling Winthrop in 1988, as Director of the Department of Toxicology and was appointed Vice President, Drug Safety worldwide in 1990. In addition, from 1990–1992, he served as Director of Sterling Winthrop’ Pharmaceutical Research Center in Alnwick, England. Upon returning to the US, Dr. Dean was appointed Executive Vice President, Drug Development, where he managed Nonclinical and Clinical Development, and Regulatory Affairs. Before joining Sterling, Dr. Dean headed the Department of Cellular and Molecular Toxicology, Chemical Industry Institute of Toxicology, Research Triangle Park, North Carolina (1982–1988). From 1979–1982, he headed the Immunotoxicology Section, National Institute of Environmental Health Services and National Toxicology Program, National Institutes of Health, Research Triangle Park. Following graduate school, Dr. Dean worked in the Department of Immunology (1972–1979, Department Director 1975–1979) at Litton Bionetics, Bethesda, Maryland doing research in tumor biology, cancer drug evaluation, and immune function in cancer patients and tumor bearing animals.
Dr. Dean has a BS in microbiology and an MS in medical microbiology from California State University at Long Beach. He earned a PhD from University of Arizona in molecular biology and minor in biochemistry (1972) from the Micro and Molecular Biology Department in the College of Medicine. Dr. Dean held adjunct professorships at the University of North Carolina, Chapel Hill and Duke University (1981–1988). He has edited five books and published 233 peer reviewed journal articles and book chapters.
In 1982, he won a Sustained High Quality Work Performance Award from the US Department of Health and Human Services, NIH. He was selected as “Outstanding Alumnus,” California State University at Long Beach in 1989 and was the first recipient of the “Lifetime Career Achievement Award” from the Immunotoxicology Specialty Section, Society of Toxicology (2000). He is a recipient of the American College of Toxicology’s “Distinguished Service Award” in 2003. In 2005, the College of Pharmacy at the University of Arizona bestowed upon him an honorary Doctor of Science degree. In September 2006, the French Republic awarded him “Chevalier” of the Legion of Honor; an award given for his “contribution to medical and pharmaceutical research.”
Professional memberships include the Society of Toxicology (Councilor 1989–1996, VP 1994–1995, President 1995–1996, Toxicology Education Foundation President, 1997); Board of Trustees, Health and Environmental Sciences Institute (ILSI/HESI) 1994–2012, President 1999–2002, Finance Committee (2002–2012), Treasurer (2004–2006 and 2008–2011); American College of Toxicology (2000–present); International Society of Immunopharmacology (Treasurer 1990–1998); and American Association of Immunologists. He served on the National Research Council’s Committee on Toxicology (1996–1999); chaired the Interagency Coordinating Committee (NIH) on Validation of Alternative Methods—LLNA Peer Review (1998); and served on the FDA Advisory Subcommittee for Non-Clinical Science (1999–2002). He was Chairman of the Scientific Advisory Committee on Alternative Toxicological Methods (SACATM) for NIEHS/NIH (2002–2005). Upon retiring, he formed Drug Development Advisors LLC in 2006 to consults on drug safety issues, drug development, regulatory strategy, and immunotoxicology issues. He held Directorships on the Board of ReSearch Pharmaceutical Services, Inc. (2007–2013); the Board of Dipexium Pharmaceuticals, Inc. (2010–2017); and the BIO-5 Institute’s Advisory Board at the University of Arizona (2007–2015). He was Co-Chair of the Bioindustries Association of Southern Arizona (BIOSA) from 2008-2015.
He holds a research professorship (2006–present) in the Department of Pharmacology and Toxicology, College of Pharmacy, University of Arizona in Tucson. Dr. Dean is a Diplomate of the American Board of Toxicology (1982–present) and Fellow of the Academy of Toxicological Sciences (2002–present).